Amgen Declares Third Quarter Dividend for 2025
Amgen, a leading biotechnology company, is one of the 30 companies that make up the Dow Jones Industrial Average. Known for its innovative medicines, Amgen specializes in treating a wide range of diseases, including cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases.
The company's operations, however, are not immune to potential challenges. An outbreak of disease or public health threat could significantly impact Amgen's product development, sales, business, and results. Additionally, government investigations, litigation, and product liability claims pose risks to Amgen's business.
Amgen's success is also influenced by various factors such as marketing success, clinical and regulatory developments, competition, manufacturing difficulties, global economic conditions, pricing pressure, reimbursement policies, and government regulations. The adoption of new tax legislation or exposure to additional tax liabilities could also affect the company's performance.
Amgen's business model relies on collaborations with third parties for the development of some product candidates and for the commercialization and sales of some commercial products. This strategy, while beneficial, introduces dependencies on sole third-party suppliers for certain raw materials, medical devices, and component parts for Amgen's products.
The protection offered by Amgen's patents may be challenged, invalidated, or circumvented by competitors, posing a threat to the company's intellectual property. Despite these challenges, Amgen's stock price remains volatile, reflecting the dynamic nature of the biotech industry.
Amgen's innovative spirit has been recognised by various prestigious organisations. In 2024, the company was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes.
For more information about Amgen, its products, and its performance, you can visit its official website, Amgen.com, or follow the company on various social media platforms including X, LinkedIn, Instagram, YouTube, and Threads. Notably, the Board of Directors of Amgen declared a $2.38 per share dividend for the third quarter of 2025, to be paid on September 12, 2025 to all stockholders of record as of the close of business on August 22, 2025.
Amgen's inclusion in the Dow Jones Industrial Average and the Nasdaq-100 Index underscores its significant role in the healthcare industry and the economy at large. The company's commitment to innovation, coupled with its resilience in the face of challenges, makes it a key player to watch in the biotech sector.
Investing in Amgen, a prominent biotech company listed in the Dow Jones Industrial Average and Nasdaq-100 Index, could be an opportunity for those interested in the finance sector, given its role in the healthcare industry and the economy. However, potential risks such as product liability claims, government investigations, and challenges to Amgen's patents may impact its business and financial performance.
